Use of mGluR5 Partial Antagonists for the Treatment of Anxiety and Other CNS Disorders

Provided is a method of treating conditions and disorders for which full mGluR5 antagonists are potentially effective, such as, e.g., anxiety, epilepsy, schizophrenia and other psychotic disorders, Parkinson's disease, addictive disorders, and the like in a subject in need of such treatment, comprising administration to such subject of a therapeutically effective amount of a partial, non-competitive mGluR5 antagonist compound of the invention.

U.S. Patent 7,531,541: Partial mGluR5 antagonists for treatment of anxiety and CNS disorders

P. Jeffrey ConnAlice RodriguezCarrie JonesDavid AlagilleGilles Tamagnan
Licensing manager: 
Tom Utley

Featured Video

Vanderbilt Patent Activity

View Vanderbilt University Patents

CTTC on Twitter